JPWO2020154645A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020154645A5 JPWO2020154645A5 JP2021542384A JP2021542384A JPWO2020154645A5 JP WO2020154645 A5 JPWO2020154645 A5 JP WO2020154645A5 JP 2021542384 A JP2021542384 A JP 2021542384A JP 2021542384 A JP2021542384 A JP 2021542384A JP WO2020154645 A5 JPWO2020154645 A5 JP WO2020154645A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- inhibitor
- itrs
- immune response
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796417P | 2019-01-24 | 2019-01-24 | |
| US201962796450P | 2019-01-24 | 2019-01-24 | |
| US62/796,417 | 2019-01-24 | ||
| US62/796,450 | 2019-01-24 | ||
| US201962800303P | 2019-02-01 | 2019-02-01 | |
| US201962800285P | 2019-02-01 | 2019-02-01 | |
| US62/800,285 | 2019-02-01 | ||
| US62/800,303 | 2019-02-01 | ||
| US201962814414P | 2019-03-06 | 2019-03-06 | |
| US201962814424P | 2019-03-06 | 2019-03-06 | |
| US62/814,414 | 2019-03-06 | ||
| US62/814,424 | 2019-03-06 | ||
| US201962857542P | 2019-06-05 | 2019-06-05 | |
| US62/857,542 | 2019-06-05 | ||
| PCT/US2020/015026 WO2020154645A1 (en) | 2019-01-24 | 2020-01-24 | Close-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518504A JP2022518504A (ja) | 2022-03-15 |
| JP2022518504A5 JP2022518504A5 (https=) | 2023-02-02 |
| JPWO2020154645A5 true JPWO2020154645A5 (https=) | 2023-02-02 |
Family
ID=71735812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542384A Pending JP2022518504A (ja) | 2019-01-24 | 2020-01-24 | 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220119840A1 (https=) |
| EP (1) | EP3914717A4 (https=) |
| JP (1) | JP2022518504A (https=) |
| KR (1) | KR20210119416A (https=) |
| CN (1) | CN113412331A (https=) |
| AU (1) | AU2020211457A1 (https=) |
| CA (1) | CA3127799A1 (https=) |
| MA (1) | MA54826A (https=) |
| MX (1) | MX2021008874A (https=) |
| SG (1) | SG11202107922QA (https=) |
| WO (1) | WO2020154645A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| SG11202005271TA (en) * | 2018-01-19 | 2020-07-29 | Generation Bio Co | Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors |
| CN108920903B (zh) * | 2018-07-09 | 2022-04-01 | 湘潭大学 | 基于朴素贝叶斯的LncRNA与疾病的关联关系预测方法及系统 |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| EP3956448A4 (en) * | 2019-04-18 | 2022-10-19 | University of Massachusetts | AIM2 INHIBITORS AND USES THEREOF |
| US20210371465A1 (en) * | 2020-03-26 | 2021-12-02 | Yale University | Method of using a tlr9 antagonist as an anti-inflammatory and anti-fibrotic agent |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| US20220090130A1 (en) * | 2020-08-23 | 2022-03-24 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| CN112138164B (zh) * | 2020-09-25 | 2022-06-03 | 徐州医科大学 | Aim2在制备降低car-t治疗毒副作用的药物中的应用 |
| EP4297728A1 (en) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| CA3230386A1 (en) * | 2021-07-23 | 2023-01-26 | Spark Therapeutics, Inc. | Methods and composition for non-viral dna delivery |
| AU2022211795A1 (en) * | 2021-08-06 | 2023-02-23 | Syte.Bio Inc. | Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector |
| JP2024532476A (ja) * | 2021-09-02 | 2024-09-05 | モレキュラー アクシオム エルエルシー | Ｎｌｒｐ３またはｎｌｒｐ１発現を調節するための組成物及び方法 |
| CN114796216A (zh) * | 2022-01-04 | 2022-07-29 | 南京医科大学 | 甲氟喹在防治全身代谢性炎症疾病中的应用 |
| JP2025532680A (ja) * | 2022-09-20 | 2025-10-01 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 抗線維化マイクロｒｎａ組成物 |
| EP4630561A1 (en) | 2022-12-09 | 2025-10-15 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
| AU2024224841A1 (en) | 2023-02-21 | 2025-08-21 | Poseida Therapeutics, Inc. | Aav piggybac transposon polynucleotide compositions and methods of use therefor |
| CN121532216A (zh) * | 2023-04-18 | 2026-02-13 | 赛仁生物技术公司 | 腺相关病毒载体组合物和使用方法 |
| WO2025064507A1 (en) | 2023-09-19 | 2025-03-27 | Poseida Therapeutics, Inc. | Compositions and methods for integration of viral vectors |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377898B2 (en) * | 2006-10-12 | 2013-02-19 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| US20140242093A1 (en) * | 2011-07-29 | 2014-08-28 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
| ES2977259T3 (es) * | 2014-11-05 | 2024-08-21 | Cartesian Therapeutics Inc | Métodos y composiciones relacionadas con nanovehículos sintéticos con rapamicina en un estado sobresaturado estable |
| WO2017152149A1 (en) * | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| US11339396B2 (en) * | 2016-06-08 | 2022-05-24 | President And Fellows Of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
-
2020
- 2020-01-24 JP JP2021542384A patent/JP2022518504A/ja active Pending
- 2020-01-24 WO PCT/US2020/015026 patent/WO2020154645A1/en not_active Ceased
- 2020-01-24 EP EP20745787.0A patent/EP3914717A4/en active Pending
- 2020-01-24 AU AU2020211457A patent/AU2020211457A1/en active Pending
- 2020-01-24 KR KR1020217024528A patent/KR20210119416A/ko active Pending
- 2020-01-24 CN CN202080010834.4A patent/CN113412331A/zh active Pending
- 2020-01-24 SG SG11202107922QA patent/SG11202107922QA/en unknown
- 2020-01-24 MA MA054826A patent/MA54826A/fr unknown
- 2020-01-24 US US17/424,199 patent/US20220119840A1/en not_active Abandoned
- 2020-01-24 MX MX2021008874A patent/MX2021008874A/es unknown
- 2020-01-24 CA CA3127799A patent/CA3127799A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020154645A5 (https=) | ||
| US11896652B2 (en) | Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues | |
| CN110606874B (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
| JP7644014B2 (ja) | 閉端ＤＮＡ（ｃｅＤＮＡ）の産生におけるＲＥＰタンパク質活性の調節 | |
| WO2019143885A1 (en) | Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors | |
| WO2019051255A1 (en) | CLOSED-ENDED DNA (CEDNA) MODIFIED | |
| CA3092059A1 (en) | Controlled expression of transgenes using close-ended dna (cedna) vectors | |
| WO2020186150A2 (en) | Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics | |
| US20230138409A1 (en) | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics | |
| KR20210148273A (ko) | 근육 발현을 위한 하이브리드 프로모터 | |
| EP3613856A1 (en) | Shrna expression cassette, polynucleotide sequence carrying same, and application thereof | |
| CA3191765A1 (en) | Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) | |
| WO2011111072A2 (en) | Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer | |
| TW202444916A (zh) | 具有改良runx3基因表現之腺相關病毒複合體及其用於預防或治療kras突變肺癌之用途 | |
| RU2812850C2 (ru) | Модуляция активности rep белка при получении днк с замкнутыми концами (зкднк) | |
| RU2021122081A (ru) | ДНК С ЗАМКНУТЫМИ КОНЦАМИ (зкДНК) И ПРИМЕНЕНИЕ В СПОСОБАХ УМЕНЬШЕНИЯ ИММУННОГО ОТВЕТА, СВЯЗАННОГО С ГЕННОЙ ТЕРАПИЕЙ ИЛИ ТЕРАПИЕЙ НУКЛЕИНОВОЙ КИСЛОТОЙ | |
| HK1252351B (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |